Form 4: AbCellera Biologics CEO Acquires 2.7 Million Share Options

AbCellera Biologics CEO, Carl L.G. Hansen, was granted 2,730,109 share options on January 1, 2025, which vest over a four-year period.

Summary

• Carl L.G. Hansen, the CEO of AbCellera Biologics Inc., was granted 2,730,109 share options on January 1, 2025.
• These options have an exercise price of $2.93 per share.
• The options vest monthly over a four-year period, with the first tranche vesting on January 1, 2026.
• The options expire on January 1, 2035.
• Following this transaction, Mr. Hansen directly owns 10,990,332 common shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of share options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector where long-term growth is a key focus.

Comparison to Industry Standards

• Granting stock options to CEOs is a common practice in the biotechnology industry, similar to companies like Regeneron Pharmaceuticals and Moderna.
• The vesting schedule of four years is also typical, aligning with long-term performance goals.
• The exercise price of $2.93 is a key factor in determining the value of the options, and will be compared to the market price of the stock at the time of vesting.

Stakeholder Impact

• Shareholders may view this positively as it aligns the CEO's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

share options, stock options, insider trading, executive compensation, AbCellera Biologics, ABCL, Carl L.G. Hansen